Sub Banner Image

FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks

Market Impact

Vandana Singh

·

July 22, 2025

·

Benzinga

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.

read more

More from

Benzinga

More

Market Impact

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.